AU2024263350A1 - Oral pharmaceutical compositions - Google Patents
Oral pharmaceutical compositionsInfo
- Publication number
- AU2024263350A1 AU2024263350A1 AU2024263350A AU2024263350A AU2024263350A1 AU 2024263350 A1 AU2024263350 A1 AU 2024263350A1 AU 2024263350 A AU2024263350 A AU 2024263350A AU 2024263350 A AU2024263350 A AU 2024263350A AU 2024263350 A1 AU2024263350 A1 AU 2024263350A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical compositions
- oral pharmaceutical
- diseases
- methods
- herpes virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to methods and compositions for treating and/or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection. In particular, provided are oral high bioavailability and long-acting pharmaceutical compositions comprising Compound 1; methods for their manufacture; and the use of said pharmaceutical compositions as a medicament and for the treatment of diseases or disorders caused by, or associated with, herpes virus.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363498398P | 2023-04-26 | 2023-04-26 | |
| US63/498,398 | 2023-04-26 | ||
| US202363522996P | 2023-06-23 | 2023-06-23 | |
| US63/522,996 | 2023-06-23 | ||
| US202463553453P | 2024-02-14 | 2024-02-14 | |
| US63/553,453 | 2024-02-14 | ||
| PCT/IB2024/053990 WO2024224304A1 (en) | 2023-04-26 | 2024-04-24 | Oral pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2024263350A1 true AU2024263350A1 (en) | 2025-11-06 |
Family
ID=91325142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024263350A Pending AU2024263350A1 (en) | 2023-04-26 | 2024-04-24 | Oral pharmaceutical compositions |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2024263350A1 (en) |
| MX (1) | MX2025012741A (en) |
| WO (1) | WO2024224304A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (en) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | THIAZOLILAMIDE DERIVATIVES |
| CR20250099A (en) | 2022-08-29 | 2025-07-29 | Assembly Biosciences Inc | Cyclic urea thiazolyl compounds for treatment of hsv |
-
2024
- 2024-04-24 AU AU2024263350A patent/AU2024263350A1/en active Pending
- 2024-04-24 WO PCT/IB2024/053990 patent/WO2024224304A1/en active Pending
-
2025
- 2025-10-24 MX MX2025012741A patent/MX2025012741A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024224304A1 (en) | 2024-10-31 |
| MX2025012741A (en) | 2025-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109970T1 (en) | PRODUCTION 6-11 CYCLOTIC OIL | |
| CA2637765A1 (en) | Benzamide and heteroarene derivatives | |
| WO2004037768A3 (en) | Phenethanolamine derivatives | |
| MX2023003627A (en) | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer. | |
| CN114787161A (en) | Pyrazolo [1,5-a ] pyridine compound and preparation method and application thereof | |
| WO2012125926A3 (en) | Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases | |
| WO2012018534A3 (en) | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases | |
| BRPI0512075A (en) | compound, process for the preparation thereof, pharmaceutical composition, use of a compound, and methods for producing a b-raf inhibiting effect, and an anticancer effect on a warm-blooded animal, and for treating a disease | |
| WO2005000863A3 (en) | 6, 11-4c-bicyclic 9a-azalide derivatives | |
| FI3840753T3 (en) | Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene | |
| AU2020231189B2 (en) | Leucine, acetyl leucine, and related analogs for treating disease | |
| AU2020278236B2 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| WO2004087728A3 (en) | 6,11-3c-bicyclic 9a-azalide derivatives | |
| EP1594885B8 (en) | Medicament for inhibiting tumour growth | |
| MX2024009403A (en) | Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead | |
| AU2024236161A1 (en) | Acylsulfonamide kat6a inhibitors | |
| MX2025002405A (en) | Pharmaceutical compositions for herpes virus | |
| AU2024307018A1 (en) | Aromatic nitrogen-containing compounds, preparation methods and medicinal uses thereof | |
| CA3088596C (en) | Crystalline form of bictegravir sodium | |
| ZA202309001B (en) | Abhd6 antagonist | |
| WO2006063039A3 (en) | 3, 6-bicyclolides | |
| AU2024263350A1 (en) | Oral pharmaceutical compositions | |
| AU2024283382A1 (en) | Anti-hiv compounds | |
| AU2024273720A1 (en) | Tetrahydronapthyridine and related analogs for inhibiting yap/taz-tead | |
| AU2023435820A1 (en) | Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives |